Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors

被引:0
|
作者
Kawaguchi, Yoshiaki [1 ]
Maruno, Atsuko [1 ]
Kawashima, Yohei [1 ]
Ito, Hiroyuki [1 ]
Ogawa, Masami [1 ]
Mine, Tetsuya [1 ]
机构
[1] Tokai Univ, Dept Gastroenterol, Sch Med, Isehara, Kanagawa 2591193, Japan
关键词
Amenorrhea; Everolimus; Neuroendocrine tumor; Pancreas; Adverse event; TUBEROUS SCLEROSIS COMPLEX; CELL CARCINOMA; DOUBLE-BLIND; EFFICACY; TRIAL; MULTICENTER; OCTREOTIDE; RAPAMYCIN;
D O I
10.3748/wjg.v20.i42.15920
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The patient was an asymptomatic 43-year-old woman. Abdominal ultrasonography and enhanced computed tomography showed a tumor lesion accompanied by multiple cystic changes in the liver and the pancreatic tail. Endoscopic ultrasound-fine needle aspiration was performed on the pancreatic tumor lesion and revealed pancreatic neuroendocrine tumor (PNET). As it was unresectable due to multiple liver metastases, the decision was made to initiate treatment with everolimus and transcatheter arterial chemoembolization. The patient ceased menstruating after the start of everolimus administration. When the administration was discontinued due to interstitial lung disease, menstruation resumed, but then again stopped with everolimus resumption. An association between everolimus and amenorrhea was highly suspected. Amenorrhea occurred as a rare adverse event of everolimus. As the younger women might be included in PNETs patients, we should put this adverse event into consideration. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:15920 / 15924
页数:5
相关论文
共 50 条
  • [21] Counting the costs of drug-related adverse events
    White, TJ
    Arakelian, A
    Rho, JP
    PHARMACOECONOMICS, 1999, 15 (05) : 445 - 458
  • [22] Counting the Costs of Drug-Related Adverse Events
    T. Jeffrey White
    Annet Arakelian
    Jay P. Rho
    PharmacoEconomics, 1999, 15 : 445 - 458
  • [24] Emergencies due to drug-related adverse effects
    Gromnica-Ihle, E
    AKTUELLE RHEUMATOLOGIE, 2001, 26 (02) : 52 - +
  • [25] When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?
    Amoroso, Vito
    Fazio, Nicola
    Mosca, Alessandra
    Roca, Elisa
    Spada, Francesca
    Foroni, Chiara
    Agazzi, Giorgio Maria
    Berruti, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (13) : 1487 - +
  • [26] Everolimus and pancreatic neuroendocrine tumors ( PNETs): Activity, resistance and how to overcome it
    Capozzi, Monica
    Caterina, Ierano
    De Divitiis, Chiara
    von Arx, Claudia
    Maiolino, Piera
    Tatangelo, Fabiana
    Cavalcanti, Ernesta
    Di Girolamo, Elena
    Iaffaioli, Rosario Vincenzo
    Scala, Stefania
    Tafuto, Salvatore
    INTERNATIONAL JOURNAL OF SURGERY, 2015, 21 : S89 - S94
  • [27] Long-Term Everolimus Treatment of Patients with Pancreatic Neuroendocrine Tumors
    Wolin, Edward M.
    CHEMOTHERAPY, 2014, 60 (03) : 143 - 150
  • [28] Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors
    Liakakos, Theodore
    Roukos, Dimitrios H.
    FUTURE ONCOLOGY, 2011, 7 (09) : 1025 - 1029
  • [29] Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview
    Martins, Diana
    Lambrescu, Ioana
    Barucca, Viola
    Fazio, Nicola
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (06): : 525 - 536
  • [30] Amenorrhea in an Adolescent Female as a Rare Adverse Event of Upadacitinib Treatment for Atopic Dermatitis
    Teng, Yan
    Tang, Yi
    Fan, Yibin
    Tao, Xiaohua
    Ding, Yang
    PATIENT PREFERENCE AND ADHERENCE, 2024, 18 : 2307 - 2310